For the treatment of adults ( ≥ 18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in below conditions:

• Nosocomial Pneumonia – indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae.
• Community-Acquired Pneumonia: 7–14 Day Treatment Regimen.
  Indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae.
• Acute bacterial sinusitis; Acute exacerbation of chronic bronchitis; Typhoid and paratyphoid fever; Complicated & Uncomplicated skin & skin structure infections; Chronic bacterial prostitis; Complicated & uncomplicated urinary tract Infections (mild to moderate); Acute pyelonephritis.